Predictability of Adjuvant Trastuzumab Benefit in N9831...

JNCI Journal of the National Cancer Institute 2012 / 01 Vol. 104; Iss. 2

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

Perez, E. A., Dueck, A. C., McCullough, A. E., Reinholz, M. M., Tenner, K. S., Davidson, N. E., Gralow, J., Harris, L. N., Kutteh, L. A., Hillman, D. W., Jenkins, R. B., Chen, B.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
104
Language:
english
Journal:
JNCI Journal of the National Cancer Institute
DOI:
10.1093/jnci/djr490
Date:
January, 2012
File:
PDF, 245 KB
english, 2012
Conversion to is in progress
Conversion to is failed